Categories
Archives
- 2026
- 2025
- 2024
- 2023
Mar
09
First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis
Nov
14
UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis
Oct
18
BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis
